Bowmark Capital has sold its majority interest in drug and alcohol testing services provider Medscreen Holdings Ltd to Concateno Plc, an AIM-listed company. The exit has generated an IRR of 52% and a return of 6.7x for Bowmark Capital.
Company has raised €20m so far over two funding rounds
HV Holtzbrinck and Lakestar also participate in the round for the dental technology startup
IK VIII held a final close in November 2016 with €1.85bn and was 87% deployed as of December 2019
With the GP's support, Bomi intends to pursue an intensive buy-and-build strategy